



Certificate No. E0C2021I215

GRN No. 81588626

Stamp Duty Paid : ₹ 101  
(Rs. Only)Penalty : ₹ 0  
(Rs. Zero Only)**Deponent**

Name: Thsti Department of Biotechnology

H.No/Floor : Na

Sector/Ward : Na

Landmark : Na

City/Village : Faridabad

District : Faridabad

State : Haryana

Phone : 98\*\*\*\*\*08

Purpose : AGREEMENT to be submitted at Anywhere

**Memorandum of Understanding (MoU) for Collaborative Research**

This Memorandum of Understanding (hereinafter the "MoU") is made on this 22<sup>nd</sup> day of October, 2021 (the "Effective Date"),

BY and BETWEEN

**Translational Health Science and Technology Institute (THSTI)**, an autonomous institute of the **Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India**, having its registered office in/at NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurugram Expressway, Post Box #04, Faridabad-121001, Haryana, India and represented by its Executive Director, which expression shall unless excluded by or repugnant to the context be deemed to mean and include its executors, administrators, representatives, successors and assigns etc., herein after referred to and called as "THSTI", PARTY OF THE FIRST PART;

AND

**University of Lucknow**, public state teaching, residential and affiliating university, based in Lucknow, Uttar Pradesh, having its registered office/ main campus located at Badshah Bagh, University Road area of the city with a second campus at Jankipuram, which expression shall unless

1 | Page

Prof. Rajeev Pandey  
Dean Research  
University of Lucknow  
Lucknow

एम. वी. सैंटो / M. V. Santo  
प्रधान - प्रशासन / Head - Administration  
ट्रांसलेशनल स्वास्थ्य विज्ञान एवं प्रौद्योगिकी संस्थान  
(भारत सरकार के विज्ञान एवं प्रौद्योगिकी विभाग का एक स्वायत्त संस्थान)  
Translational Health Science and Technology Institute  
(An autonomous institute of the Dept. of Biotechnology, India)  
NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurugram Expressway,  
PO Box No. 04, Faridabad-121001 Haryana, India

excluded by or repugnant to the context be deemed to mean and include its executors, administrators, representatives, successors and assigns etc., herein after referred to and called as "UoL" the PARTY OF THE SECOND PART.

WHEREAS "THSTI" & "UoL" are individually referred as "Party" and jointly referred as "Parties".

**RECITALS:**


- A. Translational Health Science and Technology Institute (THSTI), an autonomous Institute of DBT is established with the mandate of finding solutions for large and unique public health problems. Being situated in the NCR bio-cluster, THSTI boasts of a team with expertise in multifarious disciplines with in an inter-institutional ecosystem. THSTI has grown from an idea to an institution that is ready to take its place with leading science institutions in the country, but differentiates itself by being aimed beyond discovery research, to the fostering of application through its own efforts and through partnerships. THSTI has five areas identified as 'star' projects where we will develop world-class research and translational programmes. These are i) vaccines, ii) maternal and child health, iii) point-of-care diagnostics, iv) metabolic diseases and nutrition, and v) training in clinical and product development.
- B. The University of Lucknow strives to be among leading educational institutions of the world by consistently engaging in its endeavour through quality teaching, research and innovation rooted in the Indian value system, and working towards building an intellectual infrastructure that serves the country, its society and humanity. University of Lucknow has entered in centenary year with the mission deliver student centric research-based education with emphasis on innovation to unlock opportunities by building trusted partnerships with stakeholders, to integrate policy with practice and to enable young minds to embark upon the journey of intellectual, social and spiritual transformation.
- C. WHEREAS "THSTI" and "UoL" have come forward to jointly engage in the projects based on the development of cancer diagnostics and therapeutics. The specific sub-objectives taken up as short project recently funded by ICMR, Govt. of India may be defined overtime and appended as annexure I of this MoU.
- D. WHEREAS, the Parties desire to establish an understanding with regard to "common framework to facilitate in terms of exchange of information, material, to carry out research and to execute such other agreements as may be necessary."
- E. NOW THEREFORE, in consideration of the promises and mutual covenants hereinafter contained, the Parties hereto agree as follows:

**1. SCOPE OF THE PROJECT**


The Parties will co-operate to conduct research where research scholars and faculties of both the Institute/University may mutually share their resources to carry out the part of their research at each other's labs.

Subject to the terms of any Commercial Agreement (hereinafter defined) agreed to, each Party will have the right, in any field related to the Project or otherwise to;

2 | Page

  
Prof. Rajeev Pandey  
Dean Research  
University of Lucknow  
Lucknow

एम. वी. सैदो / M. V. Sanio  
प्रधान - प्रशासन / Head - Administration  
रासलेखन स्वास्थ्य विज्ञान एवं प्रौद्योगिकी संस्थान  
(भारत सरकार के विज्ञान एवं प्रौद्योगिकी विभाग का एक स्वायत्त संस्थान)  
Translational Health Science and Technology Institute  
(An autonomous Institute of the Dept. of Biotechnology, Govt. of India)  
NCR Biotech Science Cluster, 3rd Milestone, Faridkot-Jaipur Expressway,  
PO Box No. 64, Faridkot-121001 (Haryana), India



- a. Conduct business or research independently with third parties for this Project or any other product under the Project.
- b. Continue existing commitments or make new ones with respect to this Project or any other project.

The proposal of the project, detailing the specific is attached herewith as Annexure 1 and read along with this MoU.

## 2. DEFINITIONS

- a. **"Background Intellectual Property"** shall mean the Intellectual Property as defined herein this MOU.
- b. **"Commercial Agreement"** shall mean an agreement between the two parties for commercial aspects of the Project per clause 4b.of this MOU and embodying the spirit of this MOU and the mutually agreed terms and conditions contained herein.
- c. **"Disclosing Party"** shall mean the Party to the MOU, or its employees, agents and other authorized representatives disclosing the CONFIDENTIAL INFORMATION to the other Party (ies) to the MOU, or its employees, agents and other authorized representatives.
- d. **"Effective Date"** shall mean the date of signing of this MOU.
- e. **"Intellectual Property"** shall mean and includes the following (a) Invention including laboratory based research innovations and novelties (as defined herein) or discovery (whether patentable or not); manner, method or process of manufacture; method or principle of construction; chemical composition or formulation; biological material; computer program; integrated circuit, circuit layout or semiconductor chip layout or design; plan, drawing; or scientific, technical or engineering information or document (b) improvement, modification or development of any of the foregoing; (c) patent, application for a patent, right to apply for a patent or similar rights for or in respect of any subject matter referred to in sub-paragraphs (a) or (b) above; (d) trade secret, know-how, or right of secrecy or confidentiality in respect of any information or document or other Intellectual Property referred to in sub-paragraphs (a) or (b) above; (e) copyright or other rights in the nature of copyright subsisting in any works or other subject matter referred to in sub-paragraphs (a) or (b) above; (f) circuit layout rights
- f. **"Invention(s)"** shall mean any inventions, design techniques, process, observations, data, information, results, ideas, concepts, discoveries, developments, know-how, trade secrets, methodologies, modifications, innovations, derivatives, improvements, materials, products, laboratories formulations or other discoveries whether or not patentable.
- g. **"Receiving Party"** shall mean the Party, its employees, agents or other authorized representatives, receiving Confidential Information from the other Party, its employees, agents or other authorized representatives.
- h. **"Scope Of Work"** shall mean, in respect to the Project, the scope as detailed in this MoU), including any document or agreement executed pursuant to this MOU or as mutually agreed and executed between the Parties.
- i. **"Term"** shall mean the term or duration of this MOU commencing from the date of execution of this MOU and continuing for 2 (two) years thereafter, unless terminated earlier in accordance with Clause 8 (Termination) or extended with the agreement of both Parties in writing.

### 3. ACTIVITIES AND OBLIGATIONS

#### 3.1 ACTIVITIES AND OBLIGATIONS OF FIRST PARTY

- a. FIRST PARTY shall provide inputs to the SECOND PARTY to enable them to conduct the Project under this MOU in a professional and agreed-upon manner.
- b. FIRST PARTY shall be obliged under this MoU to prevent data, documents or other Confidential Information generated or belonging to the SECOND PARTY from unauthorised usage or falling into unauthorised hands. FIRST PARTY shall ensure that FIRST PARTY PERSONNEL working on such assignment shall sign appropriate agreements to prevent unauthorised usage and disclosure of specific data, documents or other Confidential Information of the SECOND PARTY.
- c. FIRST PARTY PERSONNEL shall make available to the SECOND PARTY and its designated personnel the results and other deliverables of the COLLABORATIVE RESEARCH as stipulated in this MoU and other subsequent agreements pertaining to the Project.
- d. FIRST PARTY shall, subject to its norms, permit personnel designated by SECOND PARTY to participate in COLLABORATIVE RESEARCH and to carry out other specific project activities envisaged under this MoU.

#### 3.2 ACTIVITIES AND OBLIGATIONS OF SECOND PARTY

- a. SECOND PARTY shall conduct the Project in collaboration with the FIRST PARTY under this MOU. SECOND PARTY shall communicate openly and participate in all discussions along with protocols and information to the FIRST PARTY in a professional and mutually agreed-upon manner.
- b. SECOND PARTY shall be obliged under this MOU to prevent data; documents or other FIRST PARTY generated or owned Confidential Information from unauthorised usage or falling into unauthorised hands. SECOND PARTY shall ensure that SECOND PARTY PERSONNEL working on such assignment shall sign appropriate agreements to prevent unauthorised usage and disclosure of specific data, documents or other Confidential Information of the FIRST PARTY.
- c. SECOND PARTY shall, subject to its norms, permit personnel designated by FIRST PARTY to participate in COLLABORATIVE RESEARCH and to carry out other specific project activities envisaged under this MoU.
- d. SECOND PARTY shall provide to the FIRST PARTY the following:
  - i. Technical Report on the developments on quarterly basis

### 4. FUNDING

- a. THSTI and UoL will develop a mutually agreeable mechanism for funding
- b. The Parties will apply for a joint funding to national and international funding agencies, when appropriate. Funding applications will identify the FIRST PARTY as a collaborating partner and will include the faculty in-charge of the of FIRST PARTY who is responsible for this collaborative research as a co-PI.

### 5. INTELLECTUAL PROPERTY

- a. Background Intellectual Property (BGIP) shall always remain the sole and exclusive property of the Party generating the BGIP. Furthermore, when FIRST PARTY receives any BGIP from the SECONDPARTY, necessary and reasonable care will be taken while using the same for the implementation of the research components. When SECOND PARTY

receives any BGIP from the FIRST PARTY, necessary and reasonable care will be taken while using the same for the implementation of the research components. Accordingly, the Parties agree to grant research-use license to the other party for the BGIP, if any only till the Term. BGIP shall include trade secrets and confidential data of the respective parties. The restrictions are not applicable to the BGIP which already form a part of the public domain at the effective date of this MoU.

- b. The Parties shall consult each other for any publication arising out of this MOU. Results of the study will not be published until prior written consent is obtained from both Parties. These publications shall duly acknowledge that the work has been carried out jointly by both Parties.
- c. Research workers/inventors of THSTI and UoL shall have joint share, i.e., 50% each in publications and copyrights arising out of this MOU. The priority in the authorship shall be decided based on the contribution in the manuscript, as per ICMJE guidelines.
- d. Any intellectual property resulting under the scope of this MoU, shall be protected using the appropriate IP. IP generated by FIRST PARTY will remain with the FIRST PARTY. IP generated by SECOND PARTY will remain with the SECOND PARTY. The cost of acquiring and maintaining the IP shall be decided by the parties together.
- e. Any revenue, earnings or distributions arising out of transfer (to any third party) of: (i) the technology or any Intellectual Property behind the product developed, generated, created, etc., under this MOU or the Commercial Agreement, or (ii) the right to commercialise, market and sell such product developed in the course of the Project pursuant to this MOU or the Commercial Agreement shall be shared equally between the Parties.

## 6. CONFIDENTIALITY

- a. In order for the PARTIES to realize the full potential of the spirit of this MOU, it may be necessary for the Parties to disclose to each other their respective proprietary and confidential information including their confidential and proprietary technical know-how and Intellectual Property and any information which the Receiving Party reasonably ought to know is proprietary to the Disclosing Party (hereinafter referred to as "Confidential Information"). Parties agree that Confidential Information provided by the Disclosing Party will be used by the Receiving Party only as provided for in this MOU, and the Receiving Party will:
  1. Hold any and all Confidential Information received pursuant to this MOU in confidence, and not disclose such information to third parties without the written consent of the Disclosing Party.
  2. Limit the disclosure of Confidential Information to those scientists, employees and officers of the Receiving Party who need such access for purposes of this cooperative effort and the Project and who have executed necessary non-disclosure agreements in line with the confidentiality obligations herein to the satisfaction of the Disclosing Party, and
  3. Not duplicate unnecessarily or use Confidential Information in any manner other than for the benefit Collaborative Research Programme envisaged under this MOU and with the prior consent of the Disclosing Party, except where mutually decided otherwise.

b. Neither THSTI nor UoL shall be subject to the restrictive obligations herein as to the use or disclosure of any information which can be shown by the Receiving Party by documentary evidence:

1. To have been in the possession of the Receiving Party prior to disclosure thereof by the Disclosing Party,
2. To be or to have become, through no lapse on the part of the Receiving Party, part of the public knowledge or literature,
3. To have lawfully become available without limitation as to its disclosure from an outside source, or
4. To have been developed by personnel of the Receiving Party independently of any Confidential Information received from the Disclosing Party and the Receiving Party is able to prove this in writing to the satisfaction of the Disclosing Party.

c. The obligations of confidentiality set forth above shall terminate on three years after the expiry of the Term or earlier termination of this MOU.

d. It is agreed that no Party shall use the names or logos of the Parties for its promotional or any purposes without prior written consent of the other party.


## 7. INDEMNIFICATION


Each Party will indemnify, defend and hold harmless the other Party, its officers, employees and agents from and against any and all third party actions, claims, demands, costs, liabilities, losses, costs and expenses (including reasonable legal costs and fees) or other damage made or brought against a Party arising out of or resulting from (i) any negligence or wilful act or omission of the other Party, or (ii) any breach of any provisions of this MOU or warranty or representation made by the other Party.

## 8. TERM AND TERMINATION

- a. This MOU will commence on "22.10.2021" and automatically terminate on 05 years thereafter, unless terminated sooner in accordance with the provisions of this MOU or if replaced with a definitive Commercial Agreement.
- b. The duration of the Parties' mutual collaboration and cooperation in respect of the Project and any distribution of revenue from commercializing the product developed under this MOU may be extended beyond the Term in accordance with the mutually agreed terms and conditions of the Commercial Agreement (if any) entered before the expiry of the Term (of this MOU).
- c. Either Party may terminate this MOU with mutual consent of the other Party or if consent is not provided, then unilaterally, upon providing the other Party written notice of not less than ninety (90) days.
- d. Any contravention of clause pertaining to Intellectual Property, by THSTI or UoL, as a result of any fraud or negligence on the part of either PARTIES will result in the termination of the contract.
- e. Either THSTI or UoL may terminate this MOU if the other Party is in breach of this MOU and does not remedy such breach within sixty (60) days of receiving a written notice of the breach.
- f. Termination or expiration of this MOU shall not affect the provisions of Clauses 5, 6 and 7 of this MOU which will survive and continue to bind the Parties beyond the termination or expiry of this MOU.

## 9. FORCE MAJEURE

  
Prof. Rajeev Pandey  
Dean Research  
University of Lucknow  
Lucknow

  
एम. वी. सिन्हा / M.V. Sinha  
प्रधान - प्रशासन / Head - Administration  
द्विभाषीय स्वास्थ्य रिसर्च केंद्र / Bilingual Health Research Center  
(भारत सरकार के शिक्षण एवं शोध) / (Ministry of Education, Government of India)  
Translational Health Science and Technology  
(एन.ए.ए.सी. / N.A.S.C.)  
Lucknow

- a. Neither Party shall be held responsible for non-fulfilment of their respective obligations under this MOU due to the exigency of one or more of the force majeure events such as but not limited to any acts of God, war, flood, earthquakes, strike, lockouts, epidemics, riots, civil commotion, natural calamity or disaster, epidemic or pandemic, restrictive action of government or regulatory authorities impacting the Project or the Parties' obligations hereunder, etc., for no fault of the affected Party; provided that on the occurrence of such events, the Party affected thereby shall give a notice in writing to the other Party within fourteen (14) days of such occurrence. If the force-majeure conditions continue beyond six months, the Parties shall then mutually decide on the future course of action. This clause will not be used for termination of this MOU/Commercial Agreement until after the expiry of three (3) months from occurrence of any event under this clause or unless mutually agreed between the Parties.

#### 10. NO AGENCY OR JOINT VENTURE

- a. No Party nor any of its respective agents, employees, independent contractors, or representatives shall be considered an agent, employee or representative of any other Party for any purpose whatsoever, have any authority to make any agreement or commitment for any other Party, nor to incur any liability or obligation in the other Party's name or on its behalf, or represent to third parties that they have any right so to bind any other Party hereto;
- b. Nothing contained in this MOU shall be construed as creating an agency, partnership or joint venture relationship among the Parties.

#### 11. NOTICES

- a. All notices and other communications required to be served on the THSTI under the terms of this MOU, shall be considered to be duly served if the same shall have been delivered to, left with or posted by registered mail to the THSTI at its last known address of business and to its official email address. Similarly, any notice to be given to the UoL shall be considered as duly served if the same shall have been delivered to, left with or posted by registered mail to the UoL at its registered address and to its official email address.

#### 12. AMENDMENTS TO THE MOU


- a. No amendment or modification of this MOU shall be valid unless the same is made in writing by both the parties or their authorized representatives and specifically stating the same to be an amendment of this MOU. The modifications/charges shall be effective from the date on which they are executed by both Parties.

#### 13. ASSIGNMENT OF THE MOU

- a. The rights and/or liabilities arising to any Party to this MOU shall not be assigned except with the written consent of the other Party and subject to such terms and conditions as may be mutually agreed upon.

#### 14. ARBITRATION

- a. Any or all dispute(s) and differences arising out of or relating to this MOU, the same shall be referred to a sole arbitrator acceptable to both Parties. The decision of the arbitral tribunal shall be final and binding on both Parties. The venue of arbitration shall be New Delhi and the arbitration proceedings shall take place in accordance with the Arbitration and Conciliation Act, 1996 in English. The Parties shall cooperate for completion of arbitration proceedings within the time lines set out under the Arbitration and Conciliation Act, 1996.

  
Prof. Rajeev Pandey  
Dean Research  
University of Lucknow  
Lucknow

एन. वी. सैंतो / M. V. Santo  
प्रधान - प्रशासन / Head - Administration  
रामलेखन स्वास्थ्य विज्ञान एवं प्रौद्योगिकी संस्थान  
(भारत सरकार के शिक्षण एवं प्रौद्योगिकी विभाग का एक स्वायत्त संस्थान)  
Translational Health Science and Technology Institute  
(An autonomous Institute of the Ministry of Health and Family Welfare, Govt. of India)

## 15. SEVERABILITY

- a. If any term and condition of this MOU is deemed unenforceable, it shall be deemed carved out of this MOU and all other provisions of this MOU shall remain in full force and effect.

## 16. ENTIRE AGREEMENT

- a. This MOU constitutes the entire understanding between the parties and supersedes all prior agreements, promises, proposals, representations, understandings and negotiations, whether written or oral, between the parties with respect to the subject matter hereof.

## 17. GOVERNING LAW

- a. This MOU shall be governed by the laws of India.


## 18. SEAL OF PARTIES

In witness whereof the Parties hereto have signed this MOU, in two originals on the day, month and year mentioned hereinbefore.

Signed on this 22.10.2021 by all the PARTIES to this MOU

### Parties

For and on behalf of THSTI



**M. V. Santo**  
Head-Administration

एच वी सैंटो / M. V. Santo  
प्रधान - प्रशासन / Head - Administration

ट्रान्स्लेशनल स्वास्थ्य विज्ञान एवं प्रौद्योगिकी संस्थान

(भारत सरकार के विज्ञान एवं प्रौद्योगिकी विभाग का एक स्वायत्त संस्थान)

Translational Health Science and Technology Institute

(An autonomous Institute of the Dept. of Biotechnology, Govt. of India)

NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway,


PO Box No. 04, Faridabad-121001 Haryana, India

For and on behalf of THSTI



**Prof. Alok Kumar Rai**  
Vice Chancellor, UoL

**Vice-Chancellor**  
Lucknow University



**Prof. Rajeev Pandey**  
Dean Research  
University of Lucknow  
Lucknow



**Project title: Evaluation of autophagic and epithelial-to-mesenchymal transition (EMT)**

**biomarkers for their clinical Impact in patients with urothelial bladder cancer**

**Research Project no.: 2019-8239**

**ICMR Ad-hoc funded research project: File no.: 5/3/8/24/2020-ITR. dated 24.3.2021**

**Summary of the work taken:**

**Background:** Autophagy has been reported to have an important role in treatment resistance in many cancer types and is gaining recognition for its role in urothelial bladder cancer. Autophagy mediated cell survival and its association with EMT induction could contribute to genetic heterogeneity, differential cellular response/resistance to drugs, disease relapse and eventual metastasis.

**Novelty:** Owing to sporadic studies available on the clinical significance of molecular mediators that participate in functional cross-talk between autophagy and EMT in urothelial tumorigenesis, biomarker characterization deserves further investigation.

**Objectives:** The present pilot study is designed to identify and validate novel biomarkers that participate in functional cross-talk between autophagy and EMT for making clinical diagnoses and assessing prognoses in a subset of bladder cancer patients.

**Methods:** Clinicohistopathological profiling of transcripts that participate in functional cross-talk between autophagy and EMT by RT-qPCR in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients. Immunophenotypic studies will be done to validate panel of novel biomarker proteins of clinical utility in NMIBC and MIBC patients. Impact of molecular determinants will be examined on the survival probabilities of patients.

**Expected outcome:** Study of alterations in molecules participating in functional cross-talk between autophagy and EMT along with clinicopathological profile of patients may allow understanding the genetic basis of bladder cancer pathogenesis. Biomarker information may help us to accurately predict tumor behavior, survival probabilities and tumor recurrence/ progression in patients. Thus greatly facilitate the objective of personalized medicine for better clinical management of patients.



**icmr**  
INDIAN COUNCIL OF  
MEDICAL RESEARCH  
Serving the nation since 1911

भारतीय आरुगिज्ञान अनुसंधान परिषद  
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार  
कल्याण मंत्रालय, भारत सरकार

Indian Council of Medical Research  
Department of Health Research, Ministry of Health  
and Family Welfare, Government of India

File No. S/3/8/24/2020-ITR

Dated:24.03.2021

To,

The Registrar,  
University of Lucknow,  
Lucknow-226007,  
(Uttar Pradesh)

**Subject:** Sanction of Budget allotment for the ICMR Ad-hoc Project entitled "Evaluation of autophagic and epithelial-to-mesenchymal transition (EMT) biomarkers for their clinical impact in patients with urothelial bladder cancer" under Dr. Minal Garg, Assistant Professor, Department of Biochemistry, University of Lucknow-226007, Uttar Pradesh.

Sir/Madam,

The Director General of the Council sanctions the above mentioned project initially for a period of one year i.e. from 04<sup>th</sup> April, 2021 to 3<sup>rd</sup> April, 2022 subject to extension up-to total duration specified in para (3) below.

The Director General of the ICMR also sanctions the budget allotment of Rs. 32,39,550/- (Rupees Thirty Two Lakh Thirty Nine Thousand Five Hundred Fifty Only) as detailed in the attached statement for the period ending, 04<sup>th</sup> April, 2021 to 3<sup>rd</sup> April, 2022.

First & Final Installment of grant-in-aid of Rs. 32,39,550/- for the 1st year will be released out of the first year budget of Rs. 32,39,550/-. The total amount of Rs. 32,39,550/- also includes the payment of Rs. 3,09,000/- of THSTI, Haryana, which will be disbursed by the University of Lucknow. The payment of the grant will be made in one installment in the name of LUCKNOW UNIVERSITY NON REC. NON MEDICAL ACCOUNT through RTGS Bank Account Number: 38831836889, IFSC Code: SBIN0014906, MICR code of bank: 226002077, State Bank of India, SBI, University of Lucknow Branch, Lucknow-226007 (A copy of Mandate Form & cancelled cheque are enclosed).

1. The first year grant will be paid generally as soon as report regarding the commencement of the project and appointment of the staff is received by the Council. The demand for payment of the subsequent installment of the grant should be placed with the Council in advance.
2. The staff appointed on the project should be paid as indicated in the attached budget statement.
3. The approved duration of the research scheme is Two years. The annual extension will be given after review of the work done on the research scheme during the previous year.
4. Five copies of the annual progress report of work done be submitted to the Council every year after completion of ten months of the project. Failure to submit the report in time may lead to termination of the project.

Contd.....2/-

5. The Institute will maintain a separate saving bank account of the receipts and the expenditure incurred on the research scheme and will furnish a utilization certificate and an audited statement of the account pertaining to the grant.
6. The grant shall be utilized after following the provisions laid down in GFR-2017 and TA rules.
7. The other terms and conditions are indicated in Annexure-I.

The receipt of this letter may please be acknowledged.

Yours faithfully,

*A. Wason*  
24/3/21

(A. Wason)

Administrative Officer

**Copy together with a copy of the budget statement forwarded for information to:**

1. Dr. Minal Garg, Assistant Professor, Department of Biochemistry, University of Lucknow-226007, Uttar Pradesh.
2. Copy together with copy of the budget statement forwarded to Accounts Section-V, ICMR for information and necessary action. The expenditure on the account may be met from the provision made for Division of ITR for Ad-hoc project on grant-in-aid basis in the budget of the Council for the financial year 2020-21.
3. Copy together with copy of the budget statement forwarded to budget section (Finance) ICMR for completion of the Council's budget.
4. IRIS cell, ICMR, ID.No. 2020-8239  
RFC No. (P-19) ITR/Ad-hoc/59/2020-21 dt.18.03.2021

## Annexure-1

File No. 5/3/8/24/2020-ITR  
 Date of start: 04.04.2021  
 Duration: 2 Years  
 IRIS cell, ICMR, ID.No. 2020-8239  
 RFC No. (P-19) ITR/Ad-hoc/59/2020-21 dt.18.03.2021

Project entitled "Evaluation of autophagic and epithelial-to-mesenchymal transition (EMT) biomarkers for their clinical impact in patients with urothelial bladder cancer" under Dr. Minal Garg, Assistant Professor, Department of Biochemistry, University of Lucknow-226007, Uttar Pradesh.

**BUDGET ESTIMATE (1<sup>st</sup> year)**  
 04.04.2021 to 03.04.2022

A : University of Lucknow		
S.No	Particular	1 <sup>st</sup> Year
I	<b>Staff</b>	1,80,000
	<b>Project Technician-III @ Rs. 18,000 p.m. for 10 months (Corresponding to PB-2 Rs.5200-20200+GradePay Rs.2800)</b>	
II	Consumables	12,75,000
	Contingency/other cost	1,00,000
	<b>Total</b>	<b>15,55,000</b>
	Overhead charges @ 3%	46,650
III	Equipment	12,78,990
IV	Travel	50,000
	<b>Grand Total</b>	<b>29,30,550</b>

B : THSTI, Haryana		
S.No	Particular	1 <sup>st</sup> Year
I	<b>Recurring</b>	
	Consumables	3,00,000
	<b>Total</b>	<b>3,00,000</b>
	Overhead charges @ 3%	9,000
	<b>Grand Total</b>	<b>3,09,000</b>
	<b>Grand Total (A+B)</b>	<b>29,30,550+3,09,000 = 32,39,550/-</b>

(Rupees Thirty Two Lakh Thirty Nine Thousand Five Hundred Fifty Only)

*A. Wason*  
 24/3/21  
 (A. Wason)  
 Administrative Officer



**icmr**  
INDIAN COUNCIL OF  
MEDICAL RESEARCH  
founded by the act of 1911

भारतीय आयुर्विज्ञान अनुसन्धान परिषद  
स्वास्थ्य अनुसन्धान विभाग, स्वास्थ्य और परिवार  
कल्याण विभाग, भारत सरकार  
Indian Council of Medical Research  
Department of Health Research, Ministry of Health  
and Family Welfare, Government of India

File No. 5/3/8/24/2020-ITR

Dated: 24.03.2021

Subject: 1<sup>st</sup> & final installment of First Year grant-in-aid of ICMR Ad-hoc Project entitled "Evaluation of autophagic and epithelial-to-mesenchymal transition (EMT) biomarkers for their clinical impact in patients with urothelial bladder cancer" under Dr. Minal Garg, Assistant Professor, Department of Biochemistry, University of Lucknow-226007, Uttar Pradesh

**MEMORANDUM:**

Reference this office letter of even number dated

The Director General, ICMR sanctions the payment of Rs. 32,39,550/- ((Rupees Thirty Two Lakh Thirty Nine Thousand Five Hundred Fifty Only) as the 1<sup>st</sup> & final installment of First year grant-in-aid for incurring expenditure in this connection with the above mentioned Research scheme. The amount of Rs. 32,39,550/- may be debited in the provision of Rs. 32,39,550/- made for the above mentioned research scheme for the 1st year i.e. from 04.04.2021 to 03.04.2022.

A formal bill for Rs. 32,39,550/- is sent herewith for payment to LUCKNOW UNIVERSITY NON REC. NON MEDICAL ACCOUNT through RTGS Bank Account Number: 38831836889, IFSC Code: SBIN0014906, MICR code of bank: 226002077, State Bank of India, SBI, University of Lucknow Branch, Lucknow-226007 (A copy of Mandate Form & cancelled cheque are enclosed).

RFC No. (P-19) ITR/Ad-hoc/59/2020-21 dt.18.03.2021

*A. Wason*  
24/3/21

(A. Wason)  
Administrative Officer

Accounts Section - V, ICMR

1. The Registrar, University of Lucknow, Lucknow-226007 (Uttar Pradesh). An amount of Rs. 32,39,550/- of 1st Year grant-in-aid is being credited to your account as per detailed submitted by you. The grant has been sanctioned on the condition laid down in our letter referred to above.
2. Dr. Minal Garg, Assistant Professor, Department of Biochemistry, University of Lucknow-226007, Uttar Pradesh.
3. IRIS cell, ICMR, ID. No. 2020-8239